Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.56 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.56 |
| ▸ | TNKS | O95271 | 1/20 | 0.56 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.56 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.56 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.56 |
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665634 | 1.00 | PARP1 (0.56) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL663872 | 1.00 | PARP1 (0.56) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL664237 | 0.95 | PARP1 (0.57) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL16809204 | 0.78 | PARP1 (0.50) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL6753927 | 0.78 | BCHE (0.46) | PARP1PARP2ALDH1A1KDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL16778562 | 0.77 | PARP1 (0.51) | PARP1PARP2TNKSPARP14PARP10 | |
| Hydrochloric Acid SCHEMBL16778564 | 0.77 | PARP1 (0.51) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL6755331 | 0.77 | ALDH1A1 (0.48) | PARP1PARP2ALDH1A1KDM4ENPC1 | |
| Veliparib SCHEMBL16758574 | 0.77 | PARP1 (0.81) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL19236099 | 0.75 | PARP1 (0.65) | PARP1PARP2TNKSPARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106432195-A | Method for preparing (R)-2-(2-methylpyrrolidine-2-yl)-1H-benzimidazole-4-carboxamide | 杭州民生药业有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20120045524-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110151023-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110151023-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885TNKS 38/4885 |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885TNKS 38/4885 |
| US-20120045524-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885TNKS 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.